Kehrloesser Sebastian, Oberst Simon, Westerhuis Willien, Wendler Astrid, Wind Anke, Blaauwgeers Harriët, Burrion Jean-Benoit, Nagy Péter, Saeter Gunnar, Gustafsson Eva, De Paoli Paolo, Lovey József, Lombardo Claudio, Philip Thierry, de Valeriola Dominique, Docter Marjet, Boomsma Femke, Saghatchian Mahasti, Svoboda Marek, Philip Irene, Monetti Francesco, Hummel Henk, McVie Gordon, Otter Renée, van Harten Wim
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, UK.
Organisation of European Cancer Institutes, Brussels, Belgium.
Mol Oncol. 2021 May;15(5):1277-1288. doi: 10.1002/1878-0261.12950. Epub 2021 Mar 30.
There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe's Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes' Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.
欧洲国家之间以及国家内部的癌症治疗结果存在持续差异，这表明（除其他原因外）在获得或提供高质量癌症护理方面存在不平等现象。欧洲政策（欧盟癌症使命和欧洲抗癌计划）目前正朝着以使命为导向的方法发展，以解决这些不平等问题。在本研究中，我们使用了欧洲癌症研究所认证与指定计划的定量和定性数据，这些数据与40家大型欧洲癌症中心有关，以描述它们目前对质量标准的遵守情况，确定所有中心共有的特征，并展示综合癌症中心的独特特点。所有获得欧洲癌症研究所认证的综合癌症中心和癌症中心都很好地遵守了与护理、多学科性和以患者为中心相关的质量标准。然而，综合癌症中心在与转化研究的数量、质量和整合相关的指标上平均得分显著更高，如高影响力出版物、临床试验活动（特别是在I期和IIa期试验中）以及作为创新早期指标的更多专利申请。然而，无论规模大小，各中心在作为大型医院内部实体运作时，在有效治理方面都存在显著差异。
